Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context
about
Screening for prostate cancerScreening for prostate cancerScreening for prostate cancer: systematic review and meta-analysis of randomised controlled trialsSpatial Genome Organization and Its Emerging Role as a Potential Diagnosis ToolCirculating biomarkers to monitor cancer progression and treatmentCurrent status of active surveillance in prostate cancerProstate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Evidence-Based AnalysisQuantifying and monitoring overdiagnosis in cancer screening: a systematic review of methodsClinical performance of serum [-2]proPSA derivatives, %p2PSA and PHI, in the detection and management of prostate cancerTreatment options for localized prostate cancerCancer/testis antigens: novel tools for discerning aggressive and non-aggressive prostate cancerOverdiagnosis and overtreatment of prostate cancerA Quest to Identify Prostate Cancer Circulating Biomarkers with a Bench-to-Bedside PotentialProstate cancer screening in Brazil: should it be done or not?Prostate cancer screening with prostate-specific antigen: A guide to the guidelinesLong-term projections of the harm-benefit trade-off in prostate cancer screening are more favorable than previous short-term estimatesAssessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening TrialAnnual report to the nation on the status of cancer, 1975-2007, featuring tumors of the brain and other nervous system.Calibrating disease progression models using population data: a critical precursor to policy development in cancer controlAnnual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates.Predicting disease progression from short biomarker series using expert advice algorithmCost-effectiveness of prostate cancer screening: a simulation study based on ERSPC data.Serum ferritin in combination with prostate-specific antigen improves predictive accuracy for prostate cancerProstate-specific antigen screening in the United States vs in the European Randomized Study of Screening for Prostate Cancer-Rotterdam.Predicting 15-year prostate cancer specific mortality after radical prostatectomy.Empirical estimates of the lead time distribution for prostate cancer based on two independent representative cohorts of men not subject to prostate-specific antigen screening.Benefits and harms of prostate cancer screening - predictions of the ONCOTYROL prostate cancer outcome and policy model.Evolution from active surveillance to focal therapy in the management of prostate cancer.Benefits and harms of computed tomography lung cancer screening strategies: a comparative modeling study for the U.S. Preventive Services Task ForceCopy number alteration burden predicts prostate cancer relapseThe high prevalence of undiagnosed prostate cancer at autopsy: implications for epidemiology and treatment of prostate cancer in the Prostate-specific Antigen-era.Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study.Prostate-specific antigen testing across the spectrum of prostate cancer.The evolving role of mass spectrometry in cancer biomarker discoveryReduced risk of prostate cancer in U.S. Men with AIDS.Quality-of-life effects of prostate-specific antigen screening.Prostate cancer in young men: an important clinical entity.Cancer risk among elderly persons with end-stage renal disease: a population-based case-control study.Long noncoding RNAs as putative biomarkers for prostate cancer detection.Patient perspective on watchful waiting/active surveillance for localized prostate cancer.
P2860
Q24201690-FBCC2248-00F3-4021-B440-4D0E7B4DAB99Q24245476-F8563CFA-64B2-425D-B0EE-32C75ADCDE27Q24608493-2FAE261D-4EC9-45B9-8E83-ECB0E28966E9Q26738275-6700DC73-3AAF-4CEB-AC11-22B98541FCE8Q26745985-2F28CDD2-395F-4A8B-874F-E0BF8EAE0921Q26766307-22372C0A-2809-4564-834D-BF6FC5950D2AQ26781093-B4A5CF81-4A12-431D-BD0A-CF1388E9EAD9Q26824867-3B1926BF-2242-45CF-B53D-7B895BC56D8EQ26824913-2AEE1155-B89C-4BE1-8312-6E80F0001B10Q26825653-FAC31A68-4702-4899-A2F3-0E78504BF8C1Q26852766-F6C48B70-011E-49D7-80FF-42525B7FE254Q26859596-BB28B585-8D1A-43D0-86CB-3D8DE83D394DQ27022638-3250142A-472B-443B-89E2-7BD12D6FDBD8Q28068688-B2824F68-D456-4A27-8528-2ECD980BC6FBQ28070347-6BF6F08B-8160-41AA-ADB7-3149F6ADA160Q28251617-16B3FC4C-4FA0-42A1-B625-222A9CE50D9EQ28286011-DDFFC286-4D5B-4EF7-BE51-6D4D1D2F9515Q28388251-9E79472B-AF59-4EB2-B1A5-D67318413F72Q30496883-1ED70121-A14B-4FD3-8A1D-97AE4E1D821CQ30538531-71D22B04-5E7C-4F6E-97BD-2AF717657B00Q30844746-B0A5D265-DA04-49C7-914C-A4F041B47CDBQ30878080-39F0AC24-CE82-4DF6-81B8-F0AC37065F2EQ33566716-2147EC7E-CFB7-43B6-A056-DFE57E5C959FQ33698755-ED66B344-127B-4DD9-BF24-C19FD9C450C0Q33759725-C3657F10-2C80-4D62-9035-9CD738E303CCQ33835863-886985FC-71B6-48AB-930F-5625EA788D28Q33836709-C23D789E-5E37-4CEC-AFBC-F3D9C5F19D37Q33933490-41EF2CE4-B0FA-46AA-B64A-17F99BF09C4AQ33978331-CA315283-2039-476C-80E7-617D962DAA4CQ34002312-043D7ECA-5915-4C0A-A580-D4FE85D76B08Q34042937-40215546-2A92-451E-81DC-0E6DF11DADEAQ34130128-5FA6E049-B65E-4510-A36E-EA02E363CDFAQ34210163-3AB88BAA-751D-4E5A-B445-74A114DCB6DEQ34215422-5089F61C-2A62-4D49-ACC9-15462F584616Q34292990-0B548AC2-2D9C-4FF8-8186-3B0ACC3DE497Q34294102-A3EB8BE2-4860-4550-8961-5CE41C68EE3AQ34314644-3461F903-06B8-4134-8215-D414D712C148Q34352780-69C0E03A-86FB-4EB4-8E0E-ECE27ED66981Q34409743-E02916DD-E50B-44C4-87C6-C2E811A37BA7Q34419421-8623222C-83C6-4869-B08F-99BB3EDB27BB
P2860
Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 10 March 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Lead time and overdiagnosis in ...... ortance of methods and context
@en
Lead time and overdiagnosis in ...... rtance of methods and context.
@nl
type
label
Lead time and overdiagnosis in ...... ortance of methods and context
@en
Lead time and overdiagnosis in ...... rtance of methods and context.
@nl
prefLabel
Lead time and overdiagnosis in ...... ortance of methods and context
@en
Lead time and overdiagnosis in ...... rtance of methods and context.
@nl
P2093
P2860
P356
P1476
Lead time and overdiagnosis in ...... ortance of methods and context
@en
P2093
Alex Tsodikov
Angela Mariotto
Elisabeth Wever
Eric Feuer
Gerrit Draisma
Harry de Koning
Roman Gulati
Ruth Etzioni
P2860
P304
P356
10.1093/JNCI/DJP001
P407
P577
2009-03-10T00:00:00Z